



an Open Access Journal by MDPI

## Therapeutic Drug Monitoring and Adverse Drug Reactions

Guest Editors:

**Dr. Engi Abd El Hady  
Algharably**

Charité–Universitätsmedizin  
Berlin, Corporate Member of  
Freie Universität Berlin and  
Humboldt-Universität zu Berlin,  
Institute of Clinical  
Pharmacology and Toxicology,  
Charitéplatz 1, 10117 Berlin,  
Germany

**Prof. Dr. Ursula Gundert-Remy**

Charité–Universitätsmedizin  
Berlin, Corporate Member of  
Freie Universität Berlin and  
Humboldt-Universität zu Berlin,  
Institute of Clinical  
Pharmacology and Toxicology,  
Charitéplatz 1, 10117 Berlin,  
Germany

Deadline for manuscript  
submissions:

**closed (29 June 2024)**

### Message from the Guest Editors

Therapeutic drug monitoring (TDM) and the prevention of adverse drug reactions (ADRs) are of utmost importance in optimizing patient care and medication safety. This issue aims to provide a comprehensive platform for researchers, clinicians and pharmacologists to present their original research, reviews and case studies related to TDM and ADRs.

The Special Issue seeks contributions covering various topics, including novel methodologies and technologies for TDM, individualized dosing strategies, biomarkers for predicting drug response and ADRs, strategies to minimize ADRs and enhance medication safety, pharmacogenomics in TDM and the implementation of TDM in clinical practice.

By exploring these themes, the Special Issue aims to enhance our understanding of drug efficacy, toxicity and personalized treatment strategies. It also seeks to highlight the importance of TDM in optimizing drug therapy, minimizing ADRs and improving patient outcomes. Researchers and clinicians are encouraged to submit their high-quality manuscripts to contribute to the advancements in therapeutic drug monitoring and adverse drug reactions.



[mdpi.com/si/178697](https://mdpi.com/si/178697)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Amélia Pilar Rauter**

Departamento de Química e  
Bioquímica (DQB) e Centro de  
Química Estrutural (CQE),  
Institute of Molecular Sciences,  
Faculdade de Ciências,  
Universidade de Lisboa, Lisboa,  
Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)  
[X@Pharmaceut\\_MDPI](https://twitter.com/Pharmaceut_MDPI)